Fosfaatit ja hypertensio aihepiiristä hakuja

Fosfaatit ja hypertensio-  aihepiiristä

LÄHDE 1.
http://www.ncbi.nlm.nih.gov/pubmed/23289181 

LÄHDE 2.Vertaa   nifedipiini, verapamil, diltiatsem
 http://www.ncbi.nlm.nih.gov/pubmed/23300272

 LÄHDE 3: PTH, fosfaatti,  aktiivi CD-vitamiini , munuiastauti
http://www.ncbi.nlm.nih.gov/pubmed/23243213

LÄHDE 4: Hypokalemia, ammoniumeritys Rh tekijä  proteiini
http://www.ncbi.nlm.nih.gov/pubmed/23195675

LÄHDE 5. Vascular remodelling- diseases,  Ins.-1,3,4,5, -tetra-cis fosfaatin biologinen funktio
http://www.ncbi.nlm.nih.gov/pubmed/2315050

LÄHDE 6: Kidney stones
http://www.ncbi.nlm.nih.gov/pubmed/23102439 

LÄHDE 7. Vatsa-aortan kalkkeutuminen,  fosfaattipitoisuus, LDL, BMD. Valtimoita kalkkeava tekijästö.
http://www.ncbi.nlm.nih.gov/pubmed/23098828

LÄHDE 8: Keuhkoarteriaan vaikuttava hypertensiotekijä
 Two endothelin (ET-1)  receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and proliferation of pulmonary arterial smooth muscle cells (PASMC). The novel ERA macitentan...
http://www.ncbi.nlm.nih.gov/pubmed/23077657

LÄHDE 9: Klotho- vanhentava  tekijä.  FGF/Klotho akseli  kalkkitasapainossa
 α-Klotho was first identified as an aging gene and was later shown to be a regulator of mineral metabolism. ... function as an obligate coreceptor for fibroblast growth factor 23 (FGF23). Phosphrus regulation of FGF23/Klotho axis is slow. ... α-Klotho is a key player that integrates "a multi-step regulatory system of calcium homeostasis" that rapidly adjusts the extracellular calcium concentration.
http://www.ncbi.nlm.nih.gov/pubmed/23023633

LÄHDE 10: RRT, renal replacement therapy
 http://www.ncbi.nlm.nih.gov/pubmed/22964569

LÄHDE 11: Nanopartikkelimenetelmällä selvitetty seerumin kalkkeutumista ja sen inhiboitumista
 Vascular and soft tissue calcification contributes to cardiovascular morbidity and mortality in both the general population and CKD ( kidney disease). Because calcium and phosphate serum concentrations are near supersaturation, the balance of inhibitors and promoters critically influences the development of calcification. An assay that measures the overall propensity for calcification to occur in serum may have clinical use. Here, we describe a nanoparticle-based assay that detects, in the presence of artificially elevated calcium and phosphate concentrations, the spontaneous transformation of spherical colloidal primary calciprotein particles (CPPs) to elongate crystalline secondary CPPs.
 http://www.ncbi.nlm.nih.gov/pubmed/22956818

LÄHDE 12.  PI(4)P signalointitiestä.  Linkki  glukoosin vaikuttamaan solusäätelyyn.Huom!
http://www.ncbi.nlm.nih.gov/pubmed/22882253

LÄHDE 13: FGF
 Elevated plasma levels of the phosphat uric hormone fibroblast growth factor 23 (FGF-23) are a hallmark of chronic kidney disease (CKD)-mineral and bone disorder. FGF-23 allows serum phosphate levels within physiological limits to be maintained in progressive CKD until end-stage renal disease is reached.
 http://www.ncbi.nlm.nih.gov/pubmed/22851630

LÄHDE 14: Linkki K1- vitamiiniaineenvaihduntaan. Matrix Gla-proteiinin osuudesta. valtimokalkkeutumsien estämisessä.
http://www.ncbi.nlm.nih.gov/pubmed/22796540


 LÄHDE 17: Paricalcitol , Calcitrioli, PTH , Ca ja fosfaatin seerumipitoisuudet 

Nutr Metab Cardiovasc Dis. 2012 Jul;22(7):547-52. doi: 10.1016/j.numecd.2012.03.010. Epub 2012 May 24.Vitamin D receptor activation and prevention of arterial ageing.

Cozzolino M, Stucchi A, Rizzo MA, Soldati L, Cusi D, Ciceri P, Brenna I, Elli F, Gallieni M.

In chronic kidney disease (CKD) patients, cardiovascular (CV) morbidity and mortality rate is higher than in the general population, because of frequently concomitant hypertension, peripheral vascular disease, heart failure, vascular calcification (VC), diabetes and mineral bone disease. Recently, another important factor associated to CV risk in CKD has been deeply investigated: vitamin D deficiency. Vitamin D Receptors (VDRs) are present in several systems and tissues and VDR activation is associated to positive effects, resulting in better blood pressure control and prevention of diabetic nephropathy.
Unfortunately, the natural, non-selective vitamin D receptor activator (VDRA), calcitriol, is associated to higher serum calcium and phosphate levels, thus worsening CV risk in CKD. Recent data showed that the selective VDRA paricalcitol might have ameliorative CV effects. The potential positive impact of the use of paricalcitol on diabetic nephropathy, cardiac disease, hypertension, and VC may open new paths in the fight against CV disease in CKD patients.
http://www.ncbi.nlm.nih.gov/pubmed/22633189 

LÄHDE 18:  FGF23 osuudesta
 http://www.ncbi.nlm.nih.gov/pubmed/22622492

LÄHDE 19: Akuutti fosfaattinefropatia  Colofosf aineesta.
http://www.ncbi.nlm.nih.gov/pubmed/22618699